InflaRx ( (IFRX)) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

Lin Tian receives funding from the Advanced Strategic Capabilities Accelerator (ASCA) and the Defence Innovation Network. Marian-Andrei Rizoiu receives funding from the Advanced Strategic Capabilities ...

SPOKANE, Wash. — A family is pleading for help to save the life of Ryan Becker, who is fighting an extremely rare and devastating illness known as Pyoderma Gangrenosum, a condition described by ...

SPOKANE, Wash. — A Spokane father is facing a devastating choice between financial ruin and his life as he battles an extremely rare disease that requires tens of thousands in monthly medication to ...

Small-cap stock investors may want to tone down their enthusiasm over the Russell 2000 breaking out. That’s because researchers have found that the so-called small-cap effect — the tendency for ...

When people are asked what a “small farm” is, they may base their answer on the number of acres or number of animals a farm has – and they often assume that there aren’t many of them. However, small, ...

InflaRx N.V. (NASDAQ:IFRX) on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma ...